Complications Over OTC: A Comprehensive Analysis of Risks, Misuse, and Regulatory Challenges in Over-the-Counter Medications

References

[1] World Health Organization, “Medication safety: Global perspective,” 2021. [Online].

[2] Indian Pharmacopoeia Commission, “Pharmacovigilance Programme of India: 2022 report,” Ministry of Health and Family Welfare, India, 2022.

[3] S. Sharma, R. Patel, and V. Kumar, “Epidemiology of over-the-counter medication-related adverse events in urban India,” Indian J. Pharmacol., vol. 54, no. 2, pp. 145–152, 2022.

[4] Food and Drug Administration, “Over-the-counter medications: Safety surveillance report,” U.S. Department of Health and Human Services, 2023.

[5] Central Drugs Standard Control Organization, “Schedule classification review: OTC medications,” Ministry of Health and Family Welfare, India, 2020.

[6] All India Confederation of Pharmacists and Licensed Chemists, “Pharmaceutical survey: OTC drug market in India,” 2021.

[7] N. Patel et al., “Community pharmacy practice patterns and OTC medication counseling in India: A multicenter survey,” Pharm. Pract., vol. 18, no. 1, pp. 1815–1815, 2020.

[8] S. Chatterjee et al., “First-generation antihistamine use and cognitive impairment in older adults: Evidence from Indian population,” J. Clin. Pharm. Ther., vol. 46, no. 3, pp. 618–626, 2021.

[9] American Pharmaceutical Association, “OTC medication safety standards,” 2020. [Online].

[10] M. Muller et al., “Laxative abuse and colonic dysfunction: Mechanisms and clinical management,” Am. J. Gastroenterol., vol. 111, no. 12, pp. 1659–1667, 2016.

[11] A. Lam et al., “Proton pump inhibitor use and vitamin B12 deficiency: Systematic review and meta-analysis,” Clin. Gastroenterol. Hepatol., vol. 20, no. 3, pp. 622–633, 2022.

[12] I. Kahan et al., “Systemic absorption of topical corticosteroids: Clinical implications,” Br. J. Dermatol., vol. 160, no. 6, pp. 1263–1271, 2009.

[13] A. Verma et al., “NSAID-induced hepatotoxicity: A retrospective analysis from Indian tertiary centers,” Indian J. Gastroenterol., vol. 40, no. 1, pp. 45–53, 2021.

[14] A. Arora et al., “Hypomagnesemia in chronic proton pump inhibitor users: Prospective study of 450 patients,” Dig. Dis. Sci., vol. 65, no. 3, pp. 789–796, 2020.

[15] V. Phadke et al., “NSAID-associated acute kidney injury: Progression to ESRD in CKD patients,” Indian J. Nephrol., vol. 29, no. 2, pp. 95–102, 2019.

[16] M. Kulkarni et al., “NSAID-induced acute interstitial nephritis: Case series from Indian tertiary centers,” Clin. Nephrol., vol. 93, no. 4, pp. 183–190, 2020.

[17] A. Verma et al., “Laxative abuse syndrome: Electrolyte abnormalities and renal function decline,” J. Clin. Gastroenterol., vol. 55, no. 2, pp. 142–148, 2021.

[18] C. Sostres et al., “Nonsteroidal anti-inflammatory drugs and upper gastrointestinal complications,” J. Clin. Gastroenterol., vol. 50, no. 5, pp. 384–393, 2016.

[19] W. Ray et al., “NSAIDs, ACE inhibitors, and diuretics in chronic kidney disease,” J. Am. Soc. Nephrol., vol. 30, no. 10, pp. 1844–1854, 2019.

[20] Antithrombotic Trialists’ Collaboration, “Cardiovascular benefits and risks of nonsteroidal anti-inflammatory drugs,” Lancet, vol. 386, no. 9989, pp. 123–133, 2015.

[21] R. Singh et al., “NSAID use and acute myocardial infarction: Case-control study in urban Indian populations,” Indian Heart J., vol. 71, no. 5, pp. 391–398, 2019.

[22] S. Sharma et al., “Pseudoephedrine-associated cardiovascular events: Retrospective analysis,” Indian J. Med. Res., vol. 148, no. 6, pp. 725–732, 2018.

[23] H. Seo et al., “Small bowel ulceration in chronic NSAID users: Capsule endoscopy findings,” Inflamm. Bowel Dis., vol. 28, no. 2, pp. 241–248, 2022.

[24] S. Sharma et al., “Upper gastrointestinal bleeding: Role of NSAIDs in Indian hospitals,” Indian J. Gastroenterol., vol. 39, no. 5, pp. 459–466, 2020.

[25] R. Gupta et al., “Laxative abuse in eating disorders: Clinical features and complications,” Int. J. Eat. Disord., vol. 54, no. 7, pp. 1185–1193, 2021.

[26] V. Rao et al., “Dextromethorphan abuse: Emerging public health concern in India,” Addiction, vol. 118, no. 2, pp. 285–293, 2023.

[27] S. Chatterjee et al., “Anticholinergic medication burden and cognitive decline in aging: Indian population cohort,” Neurology, vol. 96, no. 15, pp. e2041–e2050, 2021.

[28] N. Patel et al., “OTC medication use and fall risk in older adults: Case-control study,” J. Am. Geriatr. Soc., vol. 68, no. 10, pp. 2287–2295, 2020.

[29] A. Verma et al., “NSAID-induced acute kidney injury in dehydrated children,” Pediatr. Nephrol., vol. 36, no. 8, pp. 2345–2352, 2021.

[30] American Academy of Pediatrics, “Over-the-counter cough and cold medications in children,” Pediatrics, vol. 121, no. 4, pp. 783–787, 2008.

[31] TERIS (Teratogen Information System), “Antihistamine use in pregnancy: Risk assessment,” University of Washington, 2022.

[32] C. Thuillez et al., “NSAIDs during pregnancy: Safety in second and third trimester,” Reprod. Toxicol., vol. 42, pp. 165–173, 2013.

[33] Consumer Protection Act, “Government of India: Legal framework for consumer protection,” 2019. [Online]. Available: https://consumeraffairs.gov.in

[34] S. Sharma et al., “OTC medication-related emergency department presentations: Prospective study,” Am. J. Emerg. Med., vol. 50, pp. 156–163, 2022.

[35] S. Sharma et al., “Pharmacist-delivered counseling for NSAID users: Randomized controlled trial,” J. Pharm. Pract., vol. 35, no. 2, pp. 248–256, 2022.

[36] European Medicines Agency, “OTC medication regulatory requirements,” 2020. [Online]. Available: https://www.ema.europa.eu

[37] Therapeutic Goods Administration (Australia), “OTC medication schedule classification,” 2020. [Online]. Available: https://www.tga.gov.au

[38] Central Drugs Standard Control Organization, “Registered antacid formulations: National database,” Ministry of Health and Family Welfare, India, 2023.

[39] A. Verma et al., “Economic burden of OTC medication-related adverse events in India,” Pharmacoeconomics, vol. 39, no. 8, pp. 935–946, 2021

@article{1713238,
      author = {Galaba Yamini Padmasri, Pusunuri Pranitha, Chiruvolulanka Dharmik Ram Teja , Subhadeep Pratihar, Varshitha Asukolla},
      title = {Complications Over OTC: A Comprehensive Analysis of Risks, Misuse, and Regulatory Challenges in Over-the-Counter Medications},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {9},
      number = {7},
      pages = {68-83},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1713238.pdf},
      abstract = {Over-the-counter (OTC) medications are widely used for the management of minor and self-limiting health conditions due to their accessibility and convenience. However, inappropriate use in the absence of professional supervision has emerged as a significant contributor to preventable adverse health outcomes, particularly in low- and middle-income settings such as India. Misuse of OTC drugs commonly involves excessive dosing, prolonged consumption, polypharmacy, and failure to recognize contraindications or clinically relevant drug interactions. This review examines complications associated with the unsupervised use of commonly available OTC medications, including nonsteroidal anti-inflammatory drugs, antihistamines, antacids and acid-suppressing agents, cough suppressants, laxatives, and topical corticosteroids. The discussion integrates pharmacological mechanisms of toxicity with clinical evidence describing organ-specific adverse effects involving the gastrointestinal, renal, hepatic, cardiovascular, and neurological systems. Increased vulnerability among elderly individuals, pregnant women, children, and patients with chronic illnesses is highlighted. Regulatory challenges governing OTC medicines in India are critically evaluated in comparison with international practices, with emphasis on gaps in pharmacovigilance, labeling, and post- marketing surveillance. The role of community pharmacists in promoting rational OTC use through patient counseling and early risk identification is also discussed. Strengthening regulatory oversight and public health education is essential to reduce avoidable harm while maintaining therapeutic accessibility.},
      keywords = {Over-The-Counter Medications, Self-Medication, Adverse Drug Reactions, Pharmacovigilance, Public Health; Pharmaceutical Regulation},
      month = {January},
      doi = {https://doi.org/10.64388/IREV9I7-1713238}
  }